
Edgar Filing: IMMUNOGEN INC - Form 4

IMMUNOGEN	INC									
Form 4										
July 20, 2016										
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION							OMB APPROVAL			
	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549						OMB Number:	3235-0287		
Check this box								Expires:	January 31,	
if no longer subject to Section 16.	STATEN	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF							2005 average urs per	
Form 4 or							response			
Form 5 obligations may continue. See Instruction 1(b). Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type Resp	oonses)									
1. Name and Address of Reporting Person <u>*</u> Williams Peter J.			2. Issuer Name and Ticker or Trading Symbol IMMUNOGEN INC [IMGN]				5. Relationship of Reporting Person(s) to Issuer			
(1 +)	(Einet)		L J				(Check all applicable)			
(Last) (First) (Middle) C/O IMMUNOGEN, INC.			3. Date of Earliest Transaction (Month/Day/Year) 07/18/2016				Director 10% Owner X Officer (give title Other (specify below) below) VP, Business Development			
(Street)			4. If Amendment, Date Original			6. Individual or Joint/Group Filing(Check				
WALTHAM, N		Filed(Month/Day/Year)				Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
	(0)	(T)					reison			
(City)	(State)	(Zip)	Tab	le I - Non-l	Derivative	Securities A	Acquired, Disposed o	of, or Beneficia	lly Owned	
	Transaction Date onth/Day/Year)	2A. Deemo Execution any (Month/Da	Date, if	3. Transactio Code (Instr. 8)	Disposed	(A) or of (D)	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code V	Amount	(D) Price	(insu: 5 and 4)			
Reminder: Report	on a separate line	e for each cla	ass of sec	urities bene	ficially ow	ned directly	or indirectly.			
					Perso inform requir	ons who re nation con red to resp ays a curre	spond to the collect tained in this form ond unless the for ently valid OMB con	are not m	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount o
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

Edgar Filing: IMMUNOGEN INC - Form 4



Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Williams Peter J. C/O IMMUNOGEN, INC. WALTHAM, MA 02451			VP, Business Development				
Signatures							

/s/ Craig Barrows, attorney 07/18/2016 in fact Date

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). **
- Exercisable as to 23,334 shares commencing on July 18, 2017, 23,333 shares commencing on July 18, 2018 and 23,333 shares (1)commencing on July 18, 2019.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.